Pregnenolone Acetylsalicylate Tablets

This product is a peripheral analgesic, mainly by inhibiting the synthesis of prostate and other substances that can make pain sensitive to mechanical or chemical stimulation (such as bradykinin, histamine), but the possibility of central analgesia (possibly acting on the hypothalamus) cannot be ruled out; the anti-inflammatory mechanism of this product is still unclear, it may be because this product acts on inflamed tissues and inhibits the synthesis of prostaglandins or other substances that can cause inflammatory reactions (such as histamine) to play an anti-inflammatory role. Inhibition of the release of lysosomal enzymes and leukocyte chemotaxis may also be related to it; its antipyretic effect may act on the hypothalamic temperature regulation center to cause peripheral vasodilation, increased skin blood flow, sweating, and increased heat dissipation to play an antipyretic role. This central effect may be related to the inhibition of prostaglandin synthesis in the hypothalamus; this product inhibits platelet aggregation by inhibiting platelet cyclooxygenase and reducing prostaglandin production. This product can prevent or inhibit cell-mediated immune responses, delayed allergic reactions, reduce the number of T lymphocytes, monocytes, and eosinophils, reduce the binding ability of immunoglobulins to cell surface receptors, and inhibit the synthesis and release of interleukins, thereby reducing the transformation of T lymphocytes into lymphoblasts and alleviating the expansion of primary immune responses.

This product contains 93.0% to 107.0% of the labeled amount of pregnenolone acetylsalicylate (C30H38O5).

This product is white tablets.

Hormone drugs. Used for rheumatoid arthritis, rheumatic heart disease, etc. Also used for allergic dermatitis, contact dermatitis, iritis, keratitis, etc.

Take 1 tablet orally 3 times a day.

The more common gastrointestinal reactions (incidence 3%-9%) include nausea, vomiting, upper abdominal discomfort or pain (caused by direct stimulation of the gastric mucosa by this product), etc., which usually disappear after the dose is taken. Long-term or large-scale use may cause gastrointestinal bleeding or ulcers. Central nervous system: reversible tinnitus and hearing loss occur, which usually appear after a certain course of treatment and the concentration reaches 200-300µg/L. Allergic reaction: occurs in 0.2% of patients and manifests as asthma, angioedema or shock. Most of them are susceptible people who quickly develop respiratory difficulties after taking the medicine, and severe cases can cause death, which is called aspirin asthma. Some have the triad of aspirin allergy, asthma and nasal polyps, which are often related to genetic and environmental factors. Damage to liver and kidney function is unrelated to the size of the dose, especially when the dose is too large and the blood concentration reaches 25

1. Patients with a history of severe mental illness are prohibited from using this product. 2. Patients with active gastric or duodenal ulcers are prohibited from using this product. 3. Patients with viral, bacterial, or fungal infections that cannot be controlled with antibiotics are prohibited from using this product.

Precautions for children: Pediatric patients, especially those with fever and dehydration, are prone to toxic reactions. Acute febrile diseases, especially the use of this product in children with influenza and chickenpox, may be associated with the development of Reye’s syndrome, which is still rare in China. Precautions for pregnancy and lactation: This product easily passes through the placenta. Animal experiments show that the use of this product in the first 3 months of pregnancy can cause teratogenesis, such as spina bifida, skull cleft, facial cleft, leg deformity, and incomplete development of the central nervous system, internal organs and bones. There are also reports of fetal defects in humans after the use of this product. In addition, long-term and large-scale use of this product in the last 3 months of pregnancy can prolong the pregnancy period and increase the risk of post-term labor syndrome and antepartum hemorrhage. Use in the last 2 weeks of pregnancy can increase the risk of fetal hemorrhage or neonatal hemorrhage. Long-term use of the drug in the late pregnancy may also cause constriction or early atresia of the fetal ductus arteriosus, leading to persistent pulmonary hypertension and heart failure in the newborn. This product can be excreted in breast milk. If a nursing mother receives a large pharmacological dose of glucocorticoids, she should not breastfeed. It can be excreted in breast milk and cause adverse effects on the baby, such as growth inhibition, adrenal cortex function inhibition, etc. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

1. When used with other non-steroidal anti-inflammatory analgesics, the efficacy is not enhanced, and the bioavailability of non-steroidal anti-inflammatory drugs is reduced. In addition, gastrointestinal side effects (including ulcers and bleeding) are increased; long-term and large-scale use of this product with acetaminophen may cause kidney diseases including renal papillary necrosis, renal cancer or bladder cancer. 2. When used with any drug that can cause hypoprothrombinemia, thrombocytopenia, reduced platelet aggregation function or gastrointestinal ulcer bleeding, there is a risk of aggravating coagulation disorders and causing bleeding. 3. Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in urine and reduce the blood drug concentration. However, if the blood drug concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood drug concentration of this product can be increased to a toxic level. 4. Uric acidifying drugs can reduce the excretion of this product and increase its blood drug concentration. The addition of uricidifying drugs to patients whose blood drug concentration has reached a stable state may lead to an increase in the blood drug concentration of this product and an increase in toxic reactions. 5. The uric acid excretion effect of probenecid or sulfinpyrazone can be reduced by using this product at the same time; when the blood concentration of salicylate is 50μg/ml, it is significantly reduced, and it is even more so when it is 100-150μg/ml. Here, probenecid can reduce the clearance rate of salicylate from the kidney, thereby increasing the blood concentration of the latter. 6. Non-steroidal anti-inflammatory analgesics can increase the ulcerogenic effect of glucocorticoids. 7. It can enhance the hepatotoxicity of acetaminophen. 8. When used in combination with antacids, it can reduce the absorption of strong relaxation or dexamethasone. 9. Long-term use with anticholinergic drugs (such as atropine) can cause increased intraocular pressure. 10. Tricyclic antidepressants can aggravate the mental symptoms caused by glucocorticoids. 11. When used in combination with hypoglycemic drugs such as insulin, the dose of hypoglycemic drugs should be appropriately adjusted because it can increase the blood sugar of diabetic patients. 12. When used in combination with immunosuppressants, it can increase the risk of infection and may induce lymphoma or other lymphoproliferative diseases. 13. Glucocorticoids, especially prednisolone, can increase the metabolism and excretion of isoniazid in the liver, reducing the blood concentration and efficacy of isoniazid.

Keep away from light and store in a sealed container.

25mg

24 months

Harbin Pharmaceutical Group Co., Ltd. GENERAL Pharm. FACTORY

• Founded in:

  1994-05-19

• Address:

  No. 388, Hahei Highway, Hulan District (production base No. 109, Xuefu Road, Nangang District, No. 1, Junmin Street, Xiangfang District)

• Tax NO.:

  912301008280277137

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view